Wilson Therapeutics is a technology company.
Wilson Therapeutics has raised $40.0M across 1 funding round.
Wilson Therapeutics has raised $40.0M in total across 1 funding round.
Wilson Therapeutics has raised $40.0M in total across 1 funding round.
Wilson Therapeutics's investors include Abingworth, EQT Life Sciences, F-Prime Capital Partners, HealthCap, SR One.
Wilson Therapeutics is a Swedish biopharmaceutical company that developed novel therapies for rare copper-mediated disorders, primarily Wilson disease, a genetic condition causing toxic copper accumulation in the liver, brain, and other tissues.[1][2] Its lead product, Decuprate (WTX101), a proprietary bis-choline salt of tetrathiomolybdate, acts as a binding agent to rapidly lower copper levels, addressing unmet needs in a market without new treatments for over two decades; it received orphan drug and fast-track designations in the US and Europe.[1][2] The company served patients with this rare disease (affecting ~1 in 30,000 people) by offering a potentially superior alternative to existing therapies with debilitating side effects, showing promising Phase II data and prior testing in over 500 patients.[1][2][3] However, Wilson Therapeutics was acquired by Alexion Pharmaceuticals in 2018 for $855 million, accelerating WTX101's development within Alexion's rare disease portfolio.[1][2]
Founded in 2012 by HealthCap, a leading European life sciences venture capital firm, Wilson Therapeutics emerged to tackle Wilson disease through innovative de-coppering agents.[2][3] Key early leaders included Jonas Hansson and Hugh Rienhoff, with expertise in orphan disease therapies.[3] The idea stemmed from tetrathiomolybdate's (TTM) established profile in prior studies for Wilson disease and oncology, prompting development of the improved WTX101 formulation.[2][3] Pivotal moments included a $40 million Series B financing in 2014 co-led by Abingworth, MVM Life Science Partners, and NeoMed (with HealthCap participation), funding late-stage trials, and an IPO on Nasdaq Stockholm in May 2016.[2][3] Positive 2017 conference presentations on Decuprate's results built momentum, culminating in the 2018 Alexion acquisition.[1][2]
Wilson Therapeutics rode the rare disease therapeutics trend, capitalizing on advances in precision medicine for orphan indications with high unmet needs and premium pricing potential (e.g., Alexion's Soliris model).[1] Timing was ideal post-2010s VC surge in biotech, with Europe's life sciences ecosystem (Stockholm base) fostering IPOs and M&A; market forces like orphan drug incentives and copper metabolism insights favored copper-targeted agents.[1][2][3] The 2018 Alexion acquisition exemplified biotech's consolidation wave, influencing the ecosystem by validating TTM-based therapies and bolstering Big Pharma's rare disease pipelines amid scrutiny over drug pricing.[1]
Post-acquisition, WTX101/Decuprate advanced under Alexion (now AstraZeneca), likely reaching later-stage trials or approval, transforming Wilson disease management.[1][2] Trends like gene therapies and AI-driven rare disease discovery could complement or compete, but its established mechanism positions it strongly. Wilson Therapeutics' swift journey from VC spinout to $855M exit underscores biotech's high-reward model, potentially inspiring similar copper/rare metal disorder plays—echoing its origins in unmet patient needs.[1][2][3]
Wilson Therapeutics has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series B in April 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2014 | $40.0M Series B | Abingworth, EQT Life Sciences, F-Prime Capital Partners, HealthCap, SR One |